ELOXX PHARMACEUTICALS, INC. Revenue
ELOXX PHARMACEUTICALS, INC. (ELOX) reported Revenue of $0 for the 12-month period ending 2025-12-31, per its S-1 filed 2026-09-11.
Financial Statements › Income Statement
us-gaap:Revenues · last filed 2026-09-11
- ELOXX PHARMACEUTICALS, INC. revenues for the quarter ending 2012-12-31 was $0.00, a 100.00% decline year-over-year.
- ELOXX PHARMACEUTICALS, INC. revenues for the quarter ending 2012-09-30 was $0.00.
- ELOXX PHARMACEUTICALS, INC. revenues for the quarter ending 2012-06-30 was $0.00.
- ELOXX PHARMACEUTICALS, INC. revenues for the quarter ending 2012-03-31 was $0.00.
- ELOXX PHARMACEUTICALS, INC. revenues for fiscal 2014 was $182.23K, a 2230.59% increase from fiscal 2013.
- ELOXX PHARMACEUTICALS, INC. revenues for fiscal 2013 was $7.82K, a 96.09% decline from fiscal 2012.
- ELOXX PHARMACEUTICALS, INC. revenues for fiscal 2012 was $200.00K.
- ELOXX PHARMACEUTICALS, INC. revenues for fiscal 2010 was $140.00K.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month | Revenues 159 month | Revenues 162 month | Revenues 165 month | Revenues 168 month | Revenues 171 month | Revenues 174 month |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 S-1 · filed 2026-09-11 | |||||||||
| 2024-12-31 | $6.36M S-1 · filed 2026-09-11 | |||||||||
| 2023-12-31 | $0.00 S-1 · filed 2026-09-11 | |||||||||
| 2014-06-30 | $182.23K 10-K · filed 2016-10-13 | |||||||||
| 2013-06-30 | $7.82K 10-K · filed 2015-10-09 | |||||||||
| 2012-12-31 | $0.00 10-Q · filed 2013-02-14 | $0.00 10-Q · filed 2013-02-14 | $0.00 derived: sum of 3 quarters · filed 2013-02-14 | $0.00 derived: sum of 4 quarters · filed 2013-02-14 | $1.79M 10-Q · filed 2013-02-14 | |||||
| 2012-09-30 | $0.00 derived: 10-Q 171 month − 10-K/A 168 month · filed 2012-11-14 | $0.00 derived: sum of 2 quarters · filed 2012-11-14 | $0.00 derived: sum of 3 quarters · filed 2012-11-14 | $200.00K derived: sum of 4 quarters · filed 2013-02-14 | $1.79M 10-Q · filed 2012-11-14 | |||||
| 2012-06-30 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2012-10-26 | $0.00 derived: sum of 2 quarters · filed 2012-10-26 | $200.00K derived: sum of 3 quarters · filed 2013-02-14 | $200.00K 10-K/A · filed 2012-10-26 | $1.79M 10-K/A · filed 2012-10-26 | |||||
| 2012-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-05-14 | $200.00K derived: sum of 2 quarters · filed 2013-02-14 | $200.00K 10-Q · filed 2012-05-14 | $1.79M 10-Q · filed 2012-05-14 | ||||||
| 2011-12-31 | $200.00K 10-Q · filed 2013-02-14 | $200.00K 10-Q · filed 2013-02-14 | $1.79M 10-Q · filed 2012-02-14 | |||||||
| 2011-09-30 | $1.59M 10-Q · filed 2011-11-14 | |||||||||
| 2010-06-30 | $140.00K 10-K/A · filed 2012-10-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |